Baptista-González H, Gutiérrez-Landeros F, Rosenfeld-Mann F, Trueba-Gómez R

Language: English
References: 27
Page: 26-29
PDF size: 66.76 Kb.

Text Extraction

Introduction: The hemostatic system in newborn is a dynamic evolving process health-status dependent.
Objective. To explore the changes in coagulation inhibitors and fibrinolytic system in newborn with neonatal cholestasis, according liver damage intensity.
Methods: In a cross-sectional design, we studied fibrinolysis and coagulation inhibitor proteins, and serum ferritin (SF) in patients with neonatal cholestasis. We stratified the cases according the results of ALT or AST ‹ 100 UI (group I) and ≥100 U/L (group II).
Results: We included 24 newborn, 8 for Group I and 16 cases for group II. We documented statistical differences in ATIII values (43.4 vs 27.4%, p ‹ 0,01), plasmin inhibitor (93.5 vs 63.6%, p ‹ 0.01), SF (649 vs 1410 ug/L, p 0.01). The group II cases showed association with SF values (f 20.6, p ‹ 0.01) and plasmin inhibitor (f 40.4, p ‹ 0.01). AST and ALT were related significantly to ATIII concentrations and SF.
Discussion: We documented tendency to prothrombotic state (lower ATIII and greater plasmin inhibitor activity), with low plasminogen related to the intensity of liver dysfunction in neonatal cholestasis. We need to determine the role of iron overload in physiopathology of the disease.

REFERENCES

1. Kuhle S, Male C, Mitchell L. Developmental homeostasis: pro- and anticoagulant systems during childhood. Sem Thromb Hemost 2003; 29: 329-38.

2. Reverdiau-Moalic P, Delahousse B, Body G, Bardos P, Leroy J, Gruel Y. Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood 1996; 88: 900-6.

3. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990; 12: 95-104.

4. Andrew M, Paes B, Milner R, et al. The development of the human coagulation system in the full term infant. Blood 1987; 72: 165-172.

5. Andrew M, Paes B, Milner R, et al. Development of the coagulation system in the healthy preterm infant. Blood 1988; 72: 1651-1657.

6. Violi F, Ferro D, Quintarelli C. Clotting abnormalities in chronic liver disease. Dig Dis 1992; 10: 162-172.

7. Spector I, Corn M. Laboratory tests of hemostasis: the relation to hemorrhage in liver disease. Arch Intern Med 1967; 119: 577-582.

8. Rosenthal P. Assessing liver function and hyperbilirubinemia in the newborn. National Academy of Clinical Biochemistry. Clin Chem 1997; 43: 228-34.

9. Suchy FJ, Burdleski M, Tomar BS, Sokol RJ. Cholestatic liver disease: Working Group Report of the First World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2002; Suppl 2: S89-97.

10. Manzanares J, Medina BE. Colestasis en el recién nacido y lactante. Orientación diagnóstica. An Pediatr 2003; 58: 162-7.

11. Sansores GL, Majluf CA, Vargas VF, Labardini JL. Valores de referencia de la actividad de proteína C en adultos sanos en México. Rev Invest Clin 1994; 46: 231-5.

12. Vajro P, Amelio A, Stagni A, Paludetto R, Genovese E, Giuffre M, et al. Cholestasis in newborn infants with perinatal asphyxia. Acta Pediatr 1997; 86: 895-8.

13. Jacquemin E, Maurage C, Borderon JC, Gold F, Laugier J, Rolland JC. Early cholestasis in premature infants receiving total parenteral nutrition: a possible consequence of shock and hypoxia. Eur J Pediatr Surg 1995; 5: 259-61.

14. Jacquemin E, Lykavieris P, Chaoui N, Hadchouel M, Bernard O. Transient neonatal cholestasis: origin and outcome. J Pediatr 1998; 133: 563-7.

15. Moss RL, Das JB, Raffensperger JG. Necrotizing enterocolitis and parenteral nutrition-associated cholestasis. Nutrition 1996; 12: 340-3.

16. Esque RMT, Figueras AF, Salvia RX, Carbonell E. Amoniaco y transaminasas en sangre en el recién nacido a término afectado de asfixia perinatal. Rev Neurol 2003; 36: 801-5.

17. Andrew M. The relevance of developmental hemostasis to hemorrhagic disorders of newborns. Sem Perinat 1997; 21: 70-85.

18. Ostapowics G, Fontana R, Schiodt FV, Larson A, Davern TJ, Han SHB, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in United States. Ann Intern Med 2000; 137: 947-54.

19. Paddar U, Thapa BR, Prasad A, Sharma AK, Singh K. Natural history and risk factors in fulminant hepatic failure. Arch Dis Child 2002; 87: 54-56.

20. Lisman T, Leebeek FW, de Groot PG. Haemostatic abnormalities in patients with liver disease. J Hepatol 2002; 37: 280-7.

21. Aronis S, Platokouki H, Photopoulos S, Adamtziki E, Xanthou M. Indications of coagulation and/or fibrinolytic system activation in healthy and sick very-low-birth-weight neonates. Biol Neonate 1998; 74: 337-44.

22. Yurdakok M, Korkmaz A, Kirazli S, Aygun C, Yigit S. Global fibrinolytic capacity in early respiratory distress syndrome: a pilot study. Am J Hematol 2002; 69: 255-7.

23. Malida F, Paolo S, Sonia L, Patrizia Z, Antonio G, Vincenzo Z. Effect of delivery modalities on the physiologic inhibition system of coagulation of the neonate. Thromb Res 2002 105: 15-8.

24. Manco-Johnson MJ, Jacobson L, Hacker MR, Townsend SF, Murphy J Hay W. Development of coagulation regulatory proteins in the fetal and neonatal lamb. Pediatr Res 2002; 52: 580-88.

25. Albisetti M. The fibrinolytic system in children. Semin Thromb Hemost 2003; 29: 339-48.

26. Salonvaara M, Riikonen P, Kekomäki, Vahtera E, Mahlamäki E, Halonen P, et al. Effects of gestational age and prenatal and perinatal events on the coagulation status in premature infants. Arch Dis Child Fetal Neonatal Ed 2003; 88: F319-F323.

27. Doughty G, Kaplan SS, Sasser H, Carcillo JA. The tissue factor and Plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure. Thromb Haemost 2002; 87: 218-23.